The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2020
Filed:
Jun. 11, 2018
Boston Pharmaceuticals Inc., Cambridge, MA (US);
Catherine Ettinger, Gaithersburg, MD (US);
Jodi Karnell, Gaithersburg, MD (US);
Melissa Damschroder, Gaithersburg, MD (US);
Partha Chowdhury, Gaithersburg, MD (US);
Xiaodong Xiao, Gaithersburg, MD (US);
Ping Tsui, Gaithersburg, MD (US);
Reena Varkey, Gaithersburg, MD (US);
Stacey Drabic, Gaithersburg, MD (US);
Laura Carter, Ann Arbor, MI (US);
Ronald Herbst, Gaithersburg, MD (US);
Qun Du, Gaithersburg, MD (US);
Brian Michael Naiman, Gaithersburg, MD (US);
Boston Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.